



Delivering Science. Transforming Lives

Proactive Investors Life Sciences Webinar

10 August 2021

Dr Graham Kelly
CEO and Managing Director
NOXOPHARM LIMITED (ASX:NOX)



Discover



Develop



Deliver



DISCLAIMER



This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

* Veyonda is not registered for use in Australia or any other country

INVESTMENT PROPOSITION



A unique drug technology platform capable of multiple assets



... offering a revolutionary concept in the treatment of degenerative diseases



... such as cancer/ chronic inflammatory diseases/autoimmune diseases



... these are diseases with multiple mutations benefiting from drugs with multiple actions



Management highly experienced in drug development and drug industry



Top scientific team assembled. Collaborations with world-leading scientists



Working in areas of major industry M&A activity

Our competitive and highly valuable IP

FOUR R&D BUSINESSES IN ONE COMPANY



Veyonda®

Cancer treatment
enhancement



**Cancer Research
Pipeline**

Cancer growth
factor inhibitors



Veyonda®


Septic shock



pharmorage

Chronic inflammatory
diseases/autoimmune
diseases

1. VEYONDA® - CANCER TREATMENT ENHANCEMENT



A revolutionary concept in cancer therapy involving a drug (Veyonda®) with **multiple mechanisms of action** that aims to boost the effectiveness of other standard anti-cancer therapies

Programs



IONIC - checkpoint inhibitor therapy



DARRT - radiotherapy



CEP - chemotherapy



LuPIN - radioligand therapy

LUPIN PROGRAM

Radio-isotope injected
IV. Attaches to prostate
cancer cells



^{177}Lu tetium-
PSMA-617*

Reported median overall
survival (mOS)
15.3 months

^{177}Lu tetium-
PSMA-617
+
Veyonda

ASX Announcement 5 August 2021

LuPIN phase I/II study

- St Vincent's Hospital Sydney
- **mOS = 19.7 months**

* Novartis acquired in US\$6 billion deal in 2018 in major entry to radioligand therapy

Multiple companies now active in radioligand therapy across many cancer types

Veyonda has potential major role to play in augmenting benefit of many of these new drug therapies

2. CANCER RESEARCH PIPELINE - CANCER GROWTH FACTOR INHIBITORS



Many cancers, particularly the highly aggressive cancers, co-opt supporting healthy cells to supply growth factors that drive cancer cell growth.

NOX has identified a novel family of drugs with potential to block these signals

Programs



Brain cancer (GBM)



Pancreatic cancer


BRAIN CANCER PROGRAM

ASX Announcement 9 August 2021

Noxopharm and U.S. National Cancer Institute to Collaborate on Promising New Approach to Treatment of Brain Cancer

Major discovery by NOX scientists of new family of molecules

- ➔ Killing brain cancer cells directly
- ➔ Blocking 'helper' growth signals



3. VEYONDA® - SEPTIC SHOCK



Cytokine storm is an inappropriately excessive immune response to viral and bacterial infections

Abnormal activation of STING signalling (response to tissue damage) thought to be key trigger

Programs



Inhibition of cytokine storm



COVID-19



NOXCOVID clinical trial

Veyonda is a potent inhibitor of STING

4. PHARMORAGE - CHRONIC INFLAMMATORY DISEASES/ AUTOIMMUNE DISEASES



pharmorage

Pharmorage, a collaboration between NOX and Hudson Institute of Medical Research, has identified a new family of drug compounds with highly selective activity against STING

Programs



Chronic inflammation




Autoimmunity

Inappropriate STING signalling also now accepted as key cause of chronic inflammatory diseases (eg. rheumatoid arthritis) and autoimmune diseases (eg. motor neurone disease)

STING antagonists now centre of major industry interest as new drug class

KEY METRICS (at 6 August 2021)




News Flow (next 6 months)

-  IONIC-1, DARRT-2 & CEP-2 start patient recruitment
-  COVID-19 clinical trial reporting
-  Novel drug pipeline progress
-  Pharmorage progress

OUR VALUE PROPOSITION



What drug development companies rarely tell you



Only ~ 4% of anti-cancer drugs that enter human trials make it to market

We are significantly de-risked

Multiple shots on goal

Not limited to a single therapeutic field

Aim is to assist existing therapies, not rely on the test drug carrying the full load

Areas of major medical need and industry interest



FOR FURTHER INFORMATION:



info@noxopharm.com



www.noxopharm.com



[@Noxopharm](https://twitter.com/Noxopharm)



Discover



Develop



Deliver

